New insights into the role of nuclear factor-κB in cell growth regulation

American Journal of Pathology

Volumn 159, Issue 2, 2001, Pages 387-397

  Chen, F ^a   Castranova, V ^a   Shi, X ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

CARCINOGENESIS; CELL GROWTH; ENZYME DEGRADATION; GENE EXPRESSION; GROWTH REGULATION; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034885358     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61708-7     Document Type: Review

References (134)

1. Bridging the gap: Composition, regulation, and physiological function of the IκB kinase complex
2. Phosphorylation meets ubiquitination: The control of NF-κB activity
3. The IKK complex: An integrator of all signals that activate NF-κB?
4. New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases
5. The NF-κB and IκB proteins: New discoveries and insights
6. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses
7. Structure, regulation and function of NF-κB
8. Activators and target genes of Rel/NF-κB transcription factors
9. The Rel/NF-κB signal transduction pathway: Introduction
10. Persistent activation of NF-κB by the tax transforming protein of HTLV-1: Hijacking cellular IκB kinases
11. Prokaryotic regulation of epithelial responses by inhibition of IκBα ubiquitination
12. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB Cell
13. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK
14. IKK-1 and IKK-2: Cytokine-activated IκB kinases essential for NF-κB activation
15. IKAP is a scaffold protein of the IκB kinase complex
16. The IκB kinase (IKK) complex is tripartite and contains IKKγ but not IKAP as a regular component
17. Act1, an NF-κB-activating protein
18. CIKS, a connection to IκB kinase and stress-activated protein kinase
19. NAK is an IκB kinase-activating kinase
20. Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice
21. Apoptosis signaling
22. Death receptors: Signaling and modulation
23. Mitochondria and apoptosis
24. Apoptosis. The little devil of death
25. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
26. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
27. Molecular characterization of mitochondrial apoptosis-inducing factor
28. The inhibitors of apoptosis (IAPs) and their emerging role in cancer
29. Bcl-2 family proteins
30. Expression of bcl-X(L) restores cell survival, but not proliferation off effector differentiation, in CD28-deficient T lymphocytes
31. A model for p53-induced apoptosis
32. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress
33. ei24, a p53 response gene involved in growth suppression and apoptosis
34. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
35. Control of apoptosis by Rel/NF-κB transcription factors
36. Apoptosis and nuclear factor-κB: A tale of association and dissociation
37. NF-κB-dependent Fas ligand expression
38. Identification of two NF-κB sites in mouse CD95 ligand (Fas ligand) promoter: Functional analysis in T cell hybridoma
39. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB
40. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis
41. Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-β-deficient mice
42. Complete lack of NF-κB activity in IKK1 and IKK2 double-deficient mice: Additional defect in neurulation
43. Genetic approaches in mice to understand Rel/NF-κB and IκB function: Transgenics and knockouts
44. Female mice heterozygous for IKKγ/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti
45. NEMO/IKKγ-deficient mice model incontinentia pigmenti
46. Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice
47. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality
48. Severe liver degeneration in mice lacking the IkB kinase 2 gene
49. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration
50. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-κB-dependent pathway
51. NF-κB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition
52. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1
53. Involvement of 5′-flanking κB-like sites within bcl-x gene in silica-induced Bcl-x expression
54. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L)
55. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
56. Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: A potential role for transcription factor NF-κB
57. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1
58. The NF-κB signaling pathway is not required for Fas ligand gene induction but mediates protection from activation-induced cell death
59. Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells
60. The NF-κB/Rel family of proteins mediates Ab-induced neurotoxicity and glial activation
61. Secreted b-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-κB and stabilization of calcium homeostasis
62. Lack of the p50 subunit of nuclear factor-κB increases the vulnerability of hippocampal neurons to excitotoxic injury
63. NF-κB in neuronal plasticity and neuro-degenerative disorders
64. NF-κB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2
65. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling
66. Overexpression of the wild-type p53 gene inhibits NF-κB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells
67. HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration
68. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-κB pathway and is dependent on p53 phosphorylation
69. p300/CBP-dependent and -independent transcriptional interference between NF-κB RelA and p53
70. ATM gene product phosphorylates IκB-α
71. Lack of involvement of ataxia telangiectasia mutated (ATM) in regulation of nuclear factor-kB (NF-kB) in human diploid fibroblasts
72. DNA-dependent protein kinase phosphorylation of IκBα and IκBβ regulates NF-κB DNA binding properties
73. Role of NF-κB in p53-mediated programmed cell death
74. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator
75. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-κB loop
76. Phosphorylation of IκBα inhibits its cleavage by caspase CPP32 in vitro
77. Apoptosis promotes a caspase-induced amino-terminal truncation of IκBα that functions as a stable inhibitor of NF-κB
78. Impaired regulation of nuclear factor-κB results in apoptosis induced by γ radiation
79. A drosophila IκB kinase complex required for relish cleavage and antibacterial immunity
80. Activation of the NF-κB pathway by caspase 8 and its homologs
81. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB
82. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure
83. vCLAP, a caspase recruitment domain-containing protein of equine herpesvirus-2, persistently activates the IκB kinases through oligomerization of IKK-γ
84. A long twentieth century of the cell cycle and beyond
85. Cell cycle control, checkpoint mechanisms, and genotoxic stress
86. Role of Gadd45 in apoptosis
87. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228
88. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
89. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
90. Substrate specificity determinants of the checkpoint protein kinase Chk1
91. Induction of NF-κB DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts
92. Rapid activation of post-hepatectomy factor/nuclear factor κB in hepatocytes, a primary response in the regenerating liver
93. Cytokine induction of nuclear factor κB in cycling and growth-arrested cells. Evidence for cell cycle-independent activation
94. Initiation of liver growth by tumor necrosis factor: Deficient liver regeneration in mice lacking type I tumor necrosis factor receptor
95. Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells
96. c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition
97. Inhibition of nuclear factor-κB activation confers sensitivity to tumor necrosis factor-a by impairment of cell cycle progression in human glioma cells
98. Repression of NF-κB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators
99. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins
100. Inhibitors of mammalian G1 cyclin-dependent kinases
101. The retinoblastoma protein and cell cycle control
102. Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line
103. Limb and skin abnormalities in mice lacking IKKα
104. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase
105. Opposite effect of NF-κB and c-Jun-N-terminal kinase on p53-independent GADD45 induction by arsenite
106. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer
107. Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma
108. Rel/NF-κB/IκB proteins and cancer
109. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells
110. Elevated constitutive IκB kinase activity and IκBα phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-α transcription
111. Regulation of NF-κB activity by IκB-related proteins in adenocarcinoma cells
112. Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IκBα overexpression
113. Pathogenesis and prevention of HTLV-1-associated diseases
114. Deletion variants within the NF-κB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations
115. Malignant tumors and AIDS
116. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice
117. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50
118. Structural alterations of the NF-κB transcription factor lyt-10 in lymphoid malignancies
119. Germline configuration of nfkb2, c-rel and bcl3 in childhood acute lymphoblastic leukemia (ALL)
120. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma
121. t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: A review of 23 cases
122. Mutations in the IκBα, gene in Hodgkin's disease suggest a tumour suppressor role for IκBα
123. The hallmarks of cancer
124. The c-Jun-induced transformation process involves complex regulation of tenascin-C expression
125. The role of NF-κB/IκB proteins in cancer: Implications for novel treatment strategies
126. The transcription factor NF-κB: Control of oncogenesis and cancer therapy resistance
127. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
128. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
129. Inhibition of the NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin
130. Inhibition of NF-κB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis
131. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-κB
132. Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-κB/Rel-specific decoy oligodeoxynucleotides
133. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation
134. Nuclear factor-κB, cancer, and apoptosis